BalinBac Therapeutics, Inc., is a life science microbiome focused operating company pioneering the development of breakthrough products in gastro-intestinal disease, infectious disease, immuno-oncology, and animal nutrition.
BalinBac is focused on rapidly developing its proven and highly de-risked key antibiotic, BB-100 for curing constipation predominant irritable bowel syndrome.
BB-100 will cure some of the most deadly GI infections.